A pair of consumer advocacy groups wants antitrust authorities in Italy and Belgium to investigate Biogen (BIIB) for allegedly abusing its “position in the marketplace” by imposing an “unfair price” for Spinraza, a pricey therapy for treating a rare and fatal childhood disease called spinal muscular atrophy.

In arguing their case, the advocacy groups maintain that there is an “excessive” and “disproportionate” difference between the development costs for the medicine and what the Italian and Belgian health systems are paying. And they want authorities to take action in order to strike a balance between innovation and access.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy